793P - Prostate cancer (PCa) in elderly men - findings from South Australian Prostate Cancer Clinical Outcome Collaborative (SA-PCCOC)

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Geriatric Oncology
Prostate Cancer
Presenter Sina Vatandoust
Citation Annals of Oncology (2014) 25 (suppl_4): iv255-iv279. 10.1093/annonc/mdu336
Authors S. Vatandoust1, M. O’callaghan2, T. Kopsaftis3, S. Walsh3, M. Borg3, G. Kichenadasse1
  • 1Medical Oncology, Flinders Centre for Innovation in Cancer-FCIC, 5042 - Bedford Park/AU
  • 2Department Of Urology , Repatriation General Hospital, SA-PCCOC: South Australian Prostate Cancer Clinical Outcomes Collaborative, 5041 - Adelaide/AU
  • 3Department Of Urology , Repatriation General Hospital, SA-PCCOC: South Australian Prostate Cancer Clinical Outcomes Collaborative, 5041 - Daw Park/AU



PCa is among the most common cancers. It is the cause of death in half of cases diagnosed. Data on elderly men, especially ≥80, is limited. We describe the patient and disease characteristics and the primary cause of death (PCa versus non-PCa) in patients (pts) diagnosed when aged ≥ 80 and compare them with pts diagnosed at the age of 70-79 using data from a large clinical registry.


Data for elderly men (≥ 70 yrs) with PCa were obtained from SA-PCCOC (a longitudinal, observational registry of biopsy-proven PCa cases, throughout the Australian state of South Australia since 1998) including cause of death. Proportions were compared using a Chi squared test. A multivariable model used logistic regression to assess the variables: age at diagnosis, clinical stage and Gleason score at biopsy.


There were 601 pts in the ≥ 80 group (median age at diagnosis 84, range 80-101) and 1232 pts aged 70-79 (median age at diagnosis 74, range 70-79). At data cut-off, 431(72%) had died in the ≥ 80 group; 187 (43%; 95% CI 39-48%) caused by PCa. In the 70-79 group, 290 (24%), had died with PCa as the primary cause in 142 (49%; 95% CI 43-55%). Pts were more likely to die if diagnosed with PCa when over 80 compared to those aged 70-79 at diagnosis [OR 8.24; 95% CI 6.56-10.33]. We did not observe a statistically significant difference in the distribution of cause of death between the two groups (PCa versus non-PCa) [OR 0.80; 95% CI 0.59-1.09]. In pts aged ≥80, a Gleason score >7 at diagnosis was associated with death caused by PCa (p = 0.01); however this was not significant in multivariable analysis [OR 1.2; 95% CI 0.62-2.33]. In pts aged 70-79, death due to PCa was associated with clinical stage 3 [OR 3.56; 95% CI 1.19-11.44, p = 0.03], and Gleason score >7 [OR 3.01; 95% CI 1.22-7.66, p = 0.02] in multivariable analysis.


A large proportion of elderly men with PCa are likely to die from the disease. The proportion of elderly men (≥80 years) dying from PCa is similar to those aged 70-79. To our knowledge this is the first study focusing on the population of pts older than 80 with PCa.


All authors have declared no conflicts of interest.